P1, N=157, Terminated, BeiGene | Trial completion date: Nov 2026 --> Jul 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2025 --> Jul 2025; The research was terminated voluntarily due to changes in the company's business strategy regarding the development of BGB-24714, rather than any safety issues.

11 days ago

Trial completion date • Trial termination • Trial primary completion date

carboplatin • paclitaxel • docetaxel • BGB-24714

8ms

BGB-24714-101: A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors (clinicaltrials.gov)

P1, N=157, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting

8 months ago

Enrollment closed

carboplatin • paclitaxel • docetaxel • BGB-24714

almost2years

BGB-24714-101: Study Investigating BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors (clinicaltrials.gov)

P1, N=229, Recruiting, BeiGene | N=168 --> 229

almost 2 years ago

Enrollment change • Combination therapy

carboplatin • paclitaxel • docetaxel • BGB-24714

over2years

BGB-24714-101: Study Investigating BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors (clinicaltrials.gov)

P1, N=168, Recruiting, BeiGene | Trial completion date: Jul 2027 --> Nov 2026 | Trial primary completion date: Jan 2027 --> Dec 2025

over 2 years ago

Trial completion date • Trial primary completion date • Combination therapy

carboplatin • paclitaxel • BGB-24714

almost3years

BGB-24714, a novel oral IAP antagonist, displayed significant anti-tumor activities in preclinical models as a monotherapy and in combination with paclitaxel (AACR 2023)

BGB-24714 effectively inhibited cIAP1 by inducing its degradation in MDA-MB-231 cells, with an EC50 of 2.5 nM. BGB-24714 also potently antagonized the inhibitory interaction of XIAP with caspase-9 and induced caspase-9 autoactivation in MDA-MB-231 cells, with an EC50 of 23 nM. In a total of 25 breast cancer cell lines treated with TNFα, BGB-24714 potently inhibited the in vitro proliferation of 5 breast cancer cells with EC50 < 100 nM.

almost 3 years ago

Preclinical • Combination therapy

TNFA (Tumor Necrosis Factor-Alpha) • CASP9 (Caspase 9) • XIAP (X-Linked Inhibitor Of Apoptosis)

paclitaxel • BGB-24714